Stay updated on Radiation Doses for Immunotherapy Progression Clinical Trial

Sign up to get notified when there's something new on the Radiation Doses for Immunotherapy Progression Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Radiation Doses for Immunotherapy Progression Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated to version v2.10.0, adding two more conditions and noting that the study now includes 10 locations, while the previous version v2.9.7 has been removed.
    Difference
    0.6%
    Check dated 2024-07-23T13:58:26.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:23:36.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T14:24:32.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content version.
    Difference
    0.1%
    Check dated 2024-06-27T10:14:51.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T09:16:47.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Genetic and Rare Diseases Information Center resources: Renal Cell Carcinoma FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Interventional Model Description: This is an open label Phase 2 screening trial in subjects. Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Stereotactic Body Radiotherapy Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity. Radiation : Stereotactic Body Radiotherapy (27 Gy over 3 fractions) Biological : Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder) Primary Outcome Measures Outcome Measure Measure Description Time Frame evaluate overall response rate (ORR) in non-irradiated lesions during the first 24 weeks after treatment initiation as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in patients with limited progression receiving hypofractionated radiotherapy. ORR rate is defined as the number of patients treated to a given arm with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of patients. 24 weeks Keywords Provided by Memorial Sloan Kettering Cancer Center Radiation Immunotherapy/Checkpoint Inhibitors 18-359 Additional Relevant MeSH Terms Neoplasms Neoplasms by Site Urologic Neoplasms Urogenital Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Urologic Diseases Male Urogenital Diseases Kidney Diseases Kidney Neoplasms Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Pembrolizumab Nivolumab Ipilimumab Atezolizumab Studies a U.S. FDA-Regulated Drug Product Yes Studies a U.S. FDA-Regulated Device Product No Product Manufactured in and Exported from the U.S. No Helpful Links Provided by Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center Revision: v2.9.1'.
    Difference
    17%
    Check dated 2024-06-25T08:37:00.000Z thumbnail image

Stay in the know with updates to Radiation Doses for Immunotherapy Progression Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Radiation Doses for Immunotherapy Progression Clinical Trial page.